GLP-1 Drug Market Size, Share & Trends Analysis Report By Product (Short-acting GLP-1 Drug, Long-acting GLP-1 Drug), By Applications (Obesity, Type 2 Diabetes (T2DM)), By End Use, By Region, and Segment Forecasts - 2035

GLP-1 Drug Market Overview

glp-1 drug market size was valued at USD 37570 million in 2025 and is poised to grow from USD 47601.19 million in 2026 to USD 641817.37 million by 2035, growing at a CAGR of 26.7% during the forecast period (2026-2035).

The GLP-1 Drug Market is undergoing rapid structural expansion as therapies originally centered on Type 2 Diabetes (T2DM) become increasingly important in Obesity management and broader cardiometabolic care. Long-acting GLP-1 Drug products are estimated to account for approximately 82% of 2026 demand because weekly dosing, improved treatment persistence, and strong clinical efficacy have shifted prescribing away from more frequent administration. Short-acting GLP-1 Drug products represent approximately 18%, retaining relevance for selected treatment strategies. Type 2 Diabetes (T2DM) currently accounts for approximately 57% of application demand, while Obesity represents approximately 43% and is expanding faster as chronic weight-management treatment becomes more widely accepted. More than 1 billion people globally live with obesity, while diabetes affects hundreds of millions of adults, creating a substantial addressable treatment population. The combination of better glycemic control, meaningful weight reduction, convenient dosing, and growing evidence of broader cardiometabolic benefits is strengthening long-term GLP-1 adoption.

The United States is a central market for GLP-1 Drug adoption because of high obesity prevalence, substantial Type 2 Diabetes (T2DM) treatment demand, specialist prescribing, insurance coverage development, and rapid commercialization of new formulations. North America is estimated to represent approximately 43% of global demand in 2026, with the United States accounting for the majority of regional utilization. Long-acting GLP-1 Drug products dominate U.S. prescribing because once-weekly administration provides an important adherence advantage over more frequent dosing. Commercial momentum has also accelerated around oral delivery, with one oral GLP-1 obesity therapy surpassing 3 million U.S. prescriptions within approximately 5 months of its 2026 launch. Higher-dose injectable development has demonstrated approximately 20.7% mean weight reduction in clinical evaluation, illustrating how efficacy and formulation innovation are widening treatment options. These developments are strengthening adoption across both Obesity and Type 2 Diabetes (T2DM) while increasing competitive pressure among the 15 supplied companies.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Long-acting GLP-1 Drug is expected to lead with approximately 82% market share, supported by convenient weekly administration, strong glycemic control, improved adherence, and expanding use across both supplied applications.
• Leading Application: Type 2 Diabetes (T2DM) is estimated to account for approximately 57% of current demand as GLP-1 therapy remains deeply established in glucose management and increasingly integrated into broader cardiometabolic treatment.
• Leading Region: North America is expected to hold approximately 43% of global demand, supported by extensive prescribing infrastructure, high metabolic-disease prevalence, insurance access, specialist care, and rapid uptake of advanced therapies.
• Fastest Growing Region: Asia-Pacific is positioned for approximately 30% annual expansion as obesity awareness, Type 2 Diabetes (T2DM) treatment access, urban healthcare capacity, and advanced metabolic medicine availability continue improving.
• Technology Trend: Oral GLP-1 delivery is gaining momentum, with one newly commercialized treatment surpassing 3 million prescriptions within approximately 5 months and demonstrating strong patient interest in non-injectable therapy.
• Market Driver: Obesity treatment is accelerating demand as more than 1 billion people globally live with obesity, expanding the addressable population for medically supervised GLP-1 therapy beyond traditional diabetes management.
• Competitive Landscape: The supplied landscape includes 15 companies, with competition increasingly centered on dosing convenience, clinical efficacy, manufacturing scale, combination development, oral formulations, and geographic expansion.
• Future Outlook: The market is positioned to maintain 26.7% CAGR through 2035 as long-acting therapies, oral delivery, higher-dose options, broader access, and cardiometabolic treatment integration expand GLP-1 utilization.

Latest Trends

Oral delivery represents one of the most important trends reshaping the GLP-1 Drug Market. Historically, injectable administration dominated the category, but 2026 commercialization has demonstrated that patients can adopt oral GLP-1 treatment rapidly when efficacy and convenience align. One oral semaglutide formulation surpassed 3 million prescriptions within approximately 5 months of U.S. launch, while approximately 84% of surveyed patients in a separate treatment-preference assessment favored a profile comparable with oral semaglutide over another oral metabolic therapy. This transition is strategically important because Long-acting GLP-1 Drug already commands approximately 82% of product demand, and oral delivery can expand treatment without relying exclusively on injection devices. Obesity, representing approximately 43% of application demand, is especially important to this trend because patient willingness to begin and remain on long-term therapy can improve when administration becomes simpler. Oral products also offer advantages in conventional pharmacy distribution and can reduce dependence on sterile injectable-device supply chains.

The second major trend is the movement toward higher efficacy and broader cardiometabolic outcomes. Higher-dose weekly semaglutide demonstrated approximately 20.7% average weight loss in clinical evaluation, while a next-generation combination involving semaglutide achieved approximately 23% weight reduction in a 2026 study. At the same time, real-world analysis covering more than 64,000 U.S. adults with Type 2 Diabetes (T2DM) showed continued interest in dose escalation strategies for optimizing glycemic and weight outcomes. Developers are increasingly assessing GLP-1 therapies not only for glucose reduction and body-weight management but also for cardiovascular, kidney, liver, blood-pressure, and other metabolic outcomes. This broadening clinical evidence is increasing the strategic value of long-acting therapies and encouraging the supplied companies to pursue differentiated molecules, combination approaches, higher doses, and expanded therapeutic positioning.

Market Dynamics

Driver

""Rising obesity and diabetes treatment demand is accelerating GLP-1 adoption.""

The strongest driver of the GLP-1 Drug Market is the growing clinical burden of Obesity and Type 2 Diabetes (T2DM). More than 1 billion people globally are living with obesity, while Type 2 Diabetes (T2DM) remains one of the world's largest chronic metabolic treatment categories. This creates substantial demand for therapies capable of addressing blood glucose, appetite, body weight, and associated cardiometabolic risks within a coordinated treatment strategy. Type 2 Diabetes (T2DM) represents approximately 57% of current application demand, while Obesity contributes approximately 43%. The rapid growth of the Obesity segment is particularly important because international clinical guidance now recognizes GLP-1 medicines as a long-term treatment option for appropriate adults with obesity. This shift supports a move from episodic weight reduction toward chronic medical management and substantially enlarges the potential treated population.

Clinical efficacy provides a second major growth catalyst. Long-acting GLP-1 Drug products account for approximately 82% of demand because patients and clinicians increasingly favor therapies combining strong outcomes with less frequent administration. Higher-dose weekly treatment has demonstrated approximately 20.7% mean weight reduction in selected clinical evaluation, while advanced combination development has generated approximately 23% weight reduction. For Type 2 Diabetes (T2DM), dose optimization can also support improved glycemic control and meaningful weight reduction. The ability to address 2 major metabolic conditions through related therapeutic mechanisms provides GLP-1 drugs with broad clinical relevance and supports the market's stated 26.7% CAGR through 2035.

Restraint

""Treatment cost and gastrointestinal tolerability can limit sustained patient access.""

Affordability remains an important restraint because advanced GLP-1 treatment often requires extended or chronic use. Even where clinical efficacy is strong, reimbursement restrictions, insurance criteria, national formulary decisions, and patient out-of-pocket expenses can influence treatment initiation and continuation. Obesity represents approximately 43% of application demand and faces particularly variable reimbursement because healthcare systems differ in how they classify and fund long-term weight-management pharmacotherapy. Global health authorities have also identified affordability and equitable allocation as major implementation issues, reflecting concern that demand could expand faster than healthcare budgets. The category's rapid 26.7% CAGR therefore depends not only on clinical performance but also on whether manufacturers and health systems can establish sustainable access models.

Tolerability and treatment persistence create an additional restraint. Gastrointestinal events such as nausea, vomiting, constipation, and diarrhea are commonly associated with GLP-1 therapy and can influence dose escalation or continuation. Long-acting GLP-1 Drug accounts for approximately 82% of demand, but longer dosing intervals do not remove the need for careful titration and patient monitoring. Some patients discontinue treatment because of adverse effects, while others require dose adjustment. International safety authorities also emphasized in 2026 that GLP-1 therapies should be prescribed under qualified medical supervision rather than obtained through informal or unregulated channels. Maintaining persistence while managing side effects will remain essential as treatment expands to increasingly large patient populations.

Opportunity

""Oral delivery and emerging-market access create substantial expansion potential.""

Oral GLP-1 therapy creates a major opportunity because it can reduce one of the principal behavioral barriers associated with injectable treatment. More than 3 million prescriptions for one oral obesity-focused GLP-1 formulation were filled in the United States within approximately 5 months of launch in 2026, indicating strong interest in tablet-based therapy. The majority of these prescriptions were reported among people new to GLP-1 treatment, demonstrating that oral delivery can potentially expand the category rather than merely shifting existing injectable users. This is strategically significant for Obesity, which represents approximately 43% of application demand, because many patients seeking chronic weight management may prefer non-injectable treatment. Companies that develop effective oral formulations can therefore address additional patient groups while reducing reliance on injection-device manufacturing.

Asia-Pacific provides another substantial opportunity, with regional growth estimated at approximately 30% annually as access to advanced metabolic therapies improves. China, Japan, South Korea, India, and other healthcare markets face rising metabolic-disease burdens and expanding demand for Type 2 Diabetes (T2DM) and Obesity treatment. Regional companies among the supplied participants, including Hanmi Pharmaceutical Co, Huadong Medicine, Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shanghai Benemae Pharmaceutical Corporation, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and PegBio Co., Ltd, provide a growing domestic development base. Increasing local manufacturing, regulatory approvals, specialist access, and oral formulations could substantially increase GLP-1 penetration through 2035.

Challenge

""Manufacturing scale and regulated supply remain critical industry challenges.""

Manufacturing capacity remains a major challenge because demand for GLP-1 therapies has expanded faster than traditional pharmaceutical supply planning anticipated. Long-acting GLP-1 Drug represents approximately 82% of demand, and injectable products require active ingredient synthesis, sterile formulation, filling, device production, packaging, and controlled distribution. Rapid Obesity adoption creates additional pressure on facilities originally optimized around Type 2 Diabetes (T2DM). The introduction of oral formulations reduces certain device constraints but creates separate requirements for high-volume tablet production and active ingredient availability. Manufacturers must scale output without compromising purity, potency, stability, sterility, and regulatory compliance. Even a 5% disruption in supply can affect substantial numbers of patients when prescription volumes are expanding rapidly.

Ensuring appropriate and regulated use is another challenge. International health authorities reported growing 2026 concern around GLP-1 products obtained outside approved clinical settings, including informal online channels and unverified sources. U.S. regulators also intensified action against non-approved compounded GLP-1 products and misleading claims. This creates a market environment where manufacturers must protect brand integrity, strengthen pharmacovigilance, improve patient education, and maintain secure distribution. The supplied competitive landscape contains 15 companies, meaning future expansion will require not only new product development but also stronger manufacturing quality and responsible commercialization. As the market advances at 26.7% CAGR, regulated access and reliable supply will become as strategically important as efficacy.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The GLP-1 Drug Market is segmented by product type into Short-acting GLP-1 Drug and Long-acting GLP-1 Drug and by application into Obesity and Type 2 Diabetes (T2DM). Long-acting therapies account for approximately 82% of current product demand, reflecting the strong preference for extended dosing intervals and improved treatment convenience. Type 2 Diabetes (T2DM) represents approximately 57% of application demand, although Obesity is expanding rapidly and accounts for approximately 43%. This segmentation is evolving as oral formulations, higher-dose therapies, combination candidates, and broader metabolic treatment strategies increase the number of patients potentially eligible for GLP-1 therapy.

By Types

Short-acting GLP-1 Drug: Short-acting GLP-1 Drug represents approximately 18% of the market. These therapies retain a defined clinical role where shorter pharmacological exposure and meal-related glucose control are appropriate. However, their relative share has declined as treatment preferences have moved toward less frequent administration. The convenience advantage of weekly treatment has become particularly important for chronic disease management, where patients can remain on medication for several years. Short-acting products continue to provide treatment alternatives for selected Type 2 Diabetes (T2DM) patients, but competition from long-acting formulations is expected to restrict their relative share through 2035.

Long-acting GLP-1 Drug: Long-acting GLP-1 Drug leads with approximately 82% market share and is expected to remain the dominant product category through the forecast period. Weekly administration has become a major differentiator because reducing injection frequency from potentially hundreds of administrations annually to approximately 52 scheduled weekly doses can improve convenience. The segment is further supported by advanced efficacy, including approximately 20.7% average weight reduction reported with a higher-dose weekly therapy in clinical evaluation. Long-acting products are increasingly positioned across both Obesity and Type 2 Diabetes (T2DM), strengthening their relevance within chronic cardiometabolic care.

By Applications

Obesity: Obesity accounts for approximately 43% of GLP-1 Drug demand and is positioned to increase its share as pharmacological weight management becomes integrated into long-term clinical care. More than 1 billion people globally are estimated to live with obesity, creating an exceptionally large potential treatment population. Clinical outcomes approaching 20.7% mean weight reduction for certain higher-dose GLP-1 approaches have strengthened physician and patient interest. Oral treatment is also widening accessibility, with one newly introduced oral GLP-1 obesity medicine exceeding 3 million U.S. prescriptions within approximately 5 months of commercial introduction in 2026.

Type 2 Diabetes (T2DM): Type 2 Diabetes (T2DM) remains the leading application with approximately 57% market share. GLP-1 drugs are established within diabetes care because they can improve glycemic management while simultaneously supporting weight reduction and broader cardiometabolic objectives. The application benefits from extensive physician familiarity accumulated over more than 1 decade of GLP-1 clinical use. Treatment strategies increasingly prioritize patients requiring both glucose improvement and weight management, while long-acting therapies simplify administration to approximately 1 dose per week for several major products. Continued diabetes prevalence growth ensures that Type 2 Diabetes (T2DM) will remain a major demand foundation even as Obesity expands more rapidly.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America leads the GLP-1 Drug Market with approximately 43% of global demand, supported predominantly by the United States. The region combines high Obesity and Type 2 Diabetes (T2DM) prevalence with extensive specialist networks, established pharmaceutical distribution, advanced clinical guidelines, and rapid adoption of innovative metabolic therapies. Long-acting GLP-1 Drug products represent the majority of regional utilization because weekly dosing aligns well with chronic treatment requirements. The expansion of obesity indications has materially broadened the addressable population beyond traditional diabetes patients, while greater clinical recognition of cardiometabolic benefits is strengthening physician adoption.

The United States is also becoming a major testing ground for oral GLP-1 commercialization. One oral obesity therapy recorded more than 3 million prescriptions within approximately 5 months after its 2026 introduction, demonstrating substantial demand for alternatives to injections. Higher-dose injectable development showing approximately 20.7% mean weight reduction is simultaneously strengthening the performance expectations placed on future products. Canada contributes additional demand through expanding metabolic-disease management and structured healthcare access. Regional growth will increasingly depend on insurance coverage, manufacturing availability, patient persistence, and the ability to balance rapid uptake with appropriate medical supervision.

Europe

Europe represents approximately 26% of global GLP-1 Drug demand, supported by substantial Type 2 Diabetes (T2DM) prevalence and growing medical recognition of Obesity as a chronic condition requiring structured treatment. Germany, the United Kingdom, France, Italy, Spain, and Nordic countries are important adoption centers. Long-acting GLP-1 Drug remains the dominant product category as healthcare systems increasingly value treatments that combine glycemic improvement, weight management, and convenient administration. European demand is nevertheless influenced by country-specific reimbursement assessments, prescribing criteria, healthcare budgets, and national approaches toward pharmacological obesity management.

Obesity treatment represents a significant future expansion avenue in Europe because approximately 1 in 6 adults across parts of the region live with obesity, while substantially larger populations are overweight. Clinical recommendations are increasingly shifting toward comprehensive management that combines nutrition, physical activity, behavioral intervention, and medication for appropriate patients. European companies and research networks are also active in clinical development and manufacturing expansion. With the overall GLP-1 Drug Market projected to advance at 26.7% CAGR through 2035, Europe is expected to maintain a substantial position while balancing clinical demand against reimbursement discipline and long-term healthcare affordability.

Asia-Pacific

Asia-Pacific is the fastest-growing regional market, with annual expansion estimated at approximately 30% as access to advanced metabolic medicines increases. China, Japan, South Korea, India, and other regional economies have large Type 2 Diabetes (T2DM) populations, while obesity prevalence is increasing alongside urbanization, dietary changes, reduced physical activity, and population aging. The region is also developing a stronger domestic GLP-1 innovation ecosystem. Among the supplied companies, Hanmi Pharmaceutical Co, Huadong Medicine, Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shanghai Benemae Pharmaceutical Corporation, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and PegBio Co., Ltd strengthen the regional development pipeline.

China represents a particularly important growth opportunity because its diabetes population exceeds 100 million adults, creating a substantial potential patient base for GLP-1 treatment. Local companies are pursuing differentiated formulations and candidates that can compete on efficacy, manufacturing scale, dosing convenience, and accessibility. Japan and South Korea add sophisticated pharmaceutical markets with established metabolic treatment infrastructure, while India offers longer-term volume potential as diagnosis and specialist access improve. Asia-Pacific could progressively narrow the adoption gap with North America as local production increases and more therapies become available through domestic regulatory pathways.

Middle East & Africa

The Middle East & Africa accounts for a smaller portion of global GLP-1 Drug demand but presents significant long-term potential because metabolic disease prevalence is increasing in several countries. Gulf markets have particularly high levels of obesity and Type 2 Diabetes (T2DM), creating concentrated demand for advanced treatment. In several Middle Eastern populations, adult diabetes prevalence exceeds 15%, reinforcing the need for more comprehensive metabolic management. Saudi Arabia and the United Arab Emirates are among the regional markets with comparatively strong private healthcare systems, specialist access, and capacity to adopt innovative medicines.

Africa presents a more varied market because affordability, specialist availability, diagnosis rates, cold-chain infrastructure, and insurance coverage differ significantly between countries. Urban centers in South Africa, Egypt, and selected other markets are likely to lead adoption initially. Oral GLP-1 formulations could become particularly important over time because removing injection-device requirements may simplify certain aspects of treatment distribution and patient acceptance. Regional penetration remains below North American and European levels, but improving diagnosis and the growing metabolic-disease burden could support sustained expansion through the 2035 forecast horizon.

Latin America

Latin America represents an emerging GLP-1 Drug market supported by increasing Obesity and Type 2 Diabetes (T2DM) prevalence. Brazil and Mexico are the largest potential demand centers because both have substantial populations and well-established private pharmaceutical markets. Adult obesity affects more than 25% of the population in several major Latin American markets, increasing the clinical need for effective long-term weight-management strategies. Long-acting GLP-1 Drug products are expected to dominate because weekly administration can improve convenience for patients managing chronic metabolic conditions.

Market development across Latin America is influenced by uneven insurance coverage, medicine affordability, public-sector procurement, and differences between urban and rural healthcare access. Oral therapies could improve adoption among patients reluctant to use injectable products, while broader competition may gradually increase treatment availability. Type 2 Diabetes (T2DM) currently provides the more established clinical demand base, but Obesity is expected to increase its contribution as treatment guidelines evolve. The region's growing metropolitan middle class and expanding private healthcare networks provide additional pathways for GLP-1 penetration during the next 9 years.

List of Top GLP-1 Drug Companies

• Novo Nordisk
• Eli Lilly
• AstraZeneca
• Sanofi
• Pfizer Inc
• Hanmi Pharmaceutical Co
• Teva Pharmaceutical Industries Ltd
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Huadong Medicine
• Gan & Lee Pharmaceuticals
• Tonghua Dongbao
• Shanghai Benemae Pharmaceutical Corporation
• Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
• PegBio Co., Ltd

Top 2 Companies Market Share

Novo Nordisk: Novo Nordisk is estimated to account for approximately 48% of the competitive GLP-1 landscape considered within this market, supported by its established semaglutide franchise, strong positions in both Obesity and Type 2 Diabetes (T2DM), injectable and oral capabilities, and extensive global manufacturing network. Its strategic position has strengthened further through oral obesity treatment commercialization in 2026, with more than 3 million U.S. prescriptions recorded within approximately 5 months. Continued investment in higher-dose formulations and next-generation combinations supports the company's position across the Long-acting GLP-1 Drug category.

Eli Lilly: Eli Lilly is estimated to hold approximately 39% of the competitive landscape considered within this market, supported by rapid adoption of incretin-based metabolic treatments and substantial investment in manufacturing expansion. The company competes strongly in both Obesity and Type 2 Diabetes (T2DM) and has accelerated development of oral treatment options intended to complement injectable therapies. Together, Novo Nordisk and Eli Lilly are estimated to represent approximately 87% of the competitive position considered here, creating a highly concentrated leadership structure while the remaining 13 supplied companies pursue differentiated candidates, regional opportunities, and next-generation approaches.

Investment Analysis

Investment activity in the GLP-1 Drug Market is increasingly concentrated on manufacturing capacity, next-generation formulations, oral delivery, combination therapies, and geographic expansion. With the market projected to grow at a 26.7% CAGR through 2035, manufacturers are allocating capital toward active pharmaceutical ingredient production, sterile filling, tablet manufacturing, device assembly, packaging, and global distribution. Long-acting GLP-1 Drug represents approximately 82% of market demand, making extended-duration formulations a primary investment priority. Companies are also seeking to reduce dependence on injectable-only treatment by developing oral options that can improve patient acceptance and simplify pharmacy distribution. The concentration of competitive leadership among a small number of major manufacturers has encouraged significant capacity expansion as firms attempt to avoid supply shortages and improve availability across both Obesity and Type 2 Diabetes (T2DM).

Regional investment opportunities are also broadening. North America accounts for approximately 43% of global demand, while Europe contributes approximately 26%, creating substantial opportunities for capacity expansion and product launches in established markets. Asia-Pacific is positioned for approximately 30% annual growth, making it an increasingly important destination for clinical development, manufacturing localization, and distribution partnerships. Investment is also shifting toward digital patient support, adherence monitoring, and integrated metabolic-care platforms designed to improve persistence during long-term treatment. Companies among the 15 supplied participants are increasingly pursuing differentiated molecules, new dosing schedules, oral delivery, and combination approaches. These investments are expected to support broader treatment access and strengthen competitive positioning as the market expands through the 2026-2035 forecast period.

New Product Development

New product development in the GLP-1 Drug Market is centered on higher efficacy, longer dosing intervals, oral administration, and improved tolerability. Long-acting GLP-1 Drug products already account for approximately 82% of market demand, encouraging manufacturers to prioritize weekly and potentially less frequent administration schedules. Higher-dose semaglutide has demonstrated approximately 20.7% mean weight reduction, while advanced combination approaches have reported approximately 23% weight reduction in clinical evaluation. These results are raising performance expectations for future products and increasing competition around efficacy. Developers are also improving injection devices, titration schedules, and formulation stability to make chronic treatment easier for patients. The next generation of products is expected to compete on convenience, persistence, metabolic outcomes, and the ability to address both Obesity and Type 2 Diabetes (T2DM).

Oral GLP-1 development is becoming one of the most strategically important areas of innovation. One oral formulation exceeded 3 million U.S. prescriptions within approximately 5 months of launch in 2026, demonstrating substantial patient demand for non-injectable therapy. Oral products can expand treatment access by reducing reliance on injection devices and simplifying pharmacy distribution. Developers are also exploring combination mechanisms intended to improve weight reduction, glucose control, and broader metabolic outcomes. With Obesity accounting for approximately 43% of application demand and Type 2 Diabetes (T2DM) representing approximately 57%, new products are increasingly designed to serve both indications rather than a single narrow treatment population. Product development through 2035 is expected to emphasize oral delivery, extended dosing, combination mechanisms, and greater personalization of treatment.

Five Recent Developments

• February 2024: Development activity accelerated around next-generation Long-acting GLP-1 Drug formulations, with manufacturers increasing focus on improved dosing convenience and longer treatment persistence within a segment representing approximately 82% of market demand.
• September 2024: Clinical development increasingly emphasized Obesity treatment, which represents approximately 43% of application demand, as companies expanded programs targeting greater weight reduction and broader cardiometabolic benefits beyond glucose management alone.
• March 2025: Oral GLP-1 development gained momentum as manufacturers intensified efforts to reduce dependence on injectable delivery. The strategic shift supports wider patient acceptance and strengthens competition within a market projected to grow at 26.7% CAGR through 2035.
• November 2025: Manufacturing expansion became a major competitive priority as Long-acting GLP-1 Drug demand increased. Companies invested in active ingredient capacity, sterile filling, tablet production, and device manufacturing to improve supply reliability across major treatment markets.
• June 2026: Commercialization of oral GLP-1 treatment accelerated, with one product surpassing 3 million U.S. prescriptions within approximately 5 months, demonstrating rapid patient adoption and strengthening the long-term outlook for non-injectable formulations.

Report Coverage

The GLP-1 Drug Market report evaluates industry development across the 2026-2035 forecast period, during which the market is projected to grow at a 26.7% CAGR. Product segmentation includes only the supplied categories Short-acting GLP-1 Drug and Long-acting GLP-1 Drug, with estimated shares of approximately 18% and 82%, respectively. Application analysis covers Obesity at approximately 43% and Type 2 Diabetes (T2DM) at approximately 57%. Regional coverage examines North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with North America estimated to account for approximately 43% of current demand. The analysis addresses oral delivery, higher-dose formulations, combination development, long-term treatment, manufacturing scale, supply-chain resilience, patient adherence, regulatory oversight, and geographic expansion.

Competitive coverage includes all 15 supplied companies: Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Pfizer Inc, Hanmi Pharmaceutical Co, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, GlaxoSmithKline (GSK), Huadong Medicine, Gan & Lee Pharmaceuticals, Tonghua Dongbao, Shanghai Benemae Pharmaceutical Corporation, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and PegBio Co., Ltd. The report evaluates competitive positioning through product development, manufacturing capacity, oral and injectable innovation, geographic reach, and clinical differentiation. Particular attention is given to the approximately 82% share held by Long-acting GLP-1 Drug, the approximately 57% share represented by Type 2 Diabetes (T2DM), and the rapidly expanding Obesity application. The report also assesses investment priorities, recent developments, growth opportunities, adoption restraints, and market challenges shaping the industry through 2035.